© PR Newswire
27.10.2025
BIOA B
LISTED
STO
Health Canada Grants Authorization for Leqembi® (lecanemab)
News Preview
STOCKHOLM, Oct. 27, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment o...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
BIOA B
LISTED
STO
Health Canada Grants Authorization for Leqembi® (lecanemab)
News Preview
STOCKHOLM, Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment o...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.10.2025
EVT
LISTED
XETR
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
News Preview
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that the...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
25.10.2025
GXI
LISTED
XETR
Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
News Preview
Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
Duesseldorf, October 25, 2025. Today, Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") obtained initial findings from an investigation by an external, independent law firm, which the com......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
25.10.2025
GXI
LISTED
XETR
Erste Erkenntnisse einer externen unabhängigen Untersuchung zur Umsatzrealisierung aus Bill-and-Hold- Vereinbarungen im Geschäftsjahr 2024
News Preview
Gerresheimer AG: Erste Erkenntnisse einer externen unabhängigen Untersuchung zur Umsatzrealisierung aus Bill-and-Hold- Vereinbarungen im Geschäftsjahr 2024
Düsseldorf, 25. Oktober 2025. Die Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer"), hat heute erste Erkenntnisse aus einer von der Gesellschaft eingeleiteten externen, unabhängigen Untersu......
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
News Preview
Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation c...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2025
SOBI
LISTED
STO
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
News Preview
NASP data highlight reduction in disease burden among people living with uncontrolled gout...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
MURA
LISTED
NASDAQ
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
BAYN
LISTED
XETR
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
News Preview
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokin...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
FAGR
LISTED
EURONEXT
Fagron’s share buy-back program: Weekly update
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 October 2025 – 6PM CET...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
SOBI
LISTED
STO
Sobi showcases new data across rare inflammatory conditions at ACR 2025
News Preview
STOCKHOLM, Oct. 24, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare disease, will be presenting new data across its immunology portfolio at the annual American College of Rheumatology (ACR) Convergence 2025 meeting in...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
24.10.2025
ILM1
LISTED
XETR
Umplatzierung der Aktien von Bencis
News Preview
Pressemitteilung
Medios AG: Umplatzierung der Aktien von Bencis
Berlin, 24. Oktober 2025 – Die Medios-Gruppe („Medios“ oder „das Unternehmen“), ein führender Anbieter von Specialty Pharma in Europa, wurde darüber informiert, dass Bencis Capital Partners B.V. („Bencis“) ihren gesamten Aktienbesitz an der Medios AG umplatziert hat. Die Aktien, die ......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.10.2025
ILM1
LISTED
XETR
Reallocation of Bencis shares
News Preview
Press release
Medios AG: Block placement of Bencis shares
Berlin, October 24, 2025 – The Medios-Group (“Medios“ or “the Company”), a leading provider of Specialty Pharma in Europe, was informed that Bencis Capital Partners B.V. ("Bencis") has reallocated its entire shareholding in Medios AG. The shares, which represent a total of approx. 6.7% of ......
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D
News Preview
STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its immunotherapy SVF-001 targeting chronic hepatitis B and D at the Molecular Biology of HBV meeting in Berlin and the DeltaCure meeting in Hannover....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ORNBV
LISTED
HEL
49,164 Orion Corporation A shares converted into B shares
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 OCTOBER 2025 at 9.00 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
XFOR
LISTED
NASDAQ
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
News Preview
BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2...
Themefolio
Profiler
Peergroup
© ActuNews
23.10.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – October 23, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on October 22, 2025, from Atlas Special Oppor...
Themefolio
Profiler
Peergroup
© ActuNews
23.10.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 23 oktober 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantiekennisgeving...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
EAPI
LISTED
EURONEXT
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
News Preview
The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
LIVN
LISTED
NASDAQ
LivaNova to Present at Wolfe Research Healthcare Conference in November
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Wolfe Research Healthcare Conference 2025 in New York City. The presentation will take place...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
ORNBV
LISTED
HEL
Orion and Abzena announce exclusive commercial license for Abzena’s antibody
News Preview
ORION CORPORATION PRESS RELEASE 23 OCTOBER 2025 at 15:30 EEST Orion and Abzena announce exclusive commercial license for Abzena’s antibody...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
NSIS B
LISTED
CPH
Noma and Novonesis partner to scale deliciousness
News Preview
Noma and Novonesis partner to scale deliciousnessNoma, hailed as one of the world’s best restaurants, is joining forces with Novonesis, the global leader in biosolutions, to take deliciousness to the next level. Together, they’re fusing culinary craft with biology to create flavors and products that are healthier, tastier, and better for the planet...
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2025
VITR
LISTED
STO
Vitrolife AB (publ) - Interim report Q3, 2025: Strong growth in Americas
News Preview
GOTHENBURG, Sweden, Oct. 23, 2025 /PRNewswire/ --
Third quarter
Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local curren...
Themefolio
Profiler
Peergroup
© ActuNews
23.10.2025
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million
News Preview
Subscription and guarantee commitments totaling €5.9 million, representing 75.5% of the envisaged capital increase
Subscription price: €1.80 per share, representing a 29.4% discount to the closing price of the share on October 22, 2025
Subscription ratio: 6 new shares for 13 existing shares
Detachment of preferential subscr...
Themefolio
Profiler
Peergroup
© ActuNews
23.10.2025
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma annonce le lancement d'une augmentation de capital avec maintien du DPS d'un montant d'environ 8M EUR
News Preview
Engagements de souscription et de garantie à hauteur de 5,9M€ représentant 75,5% de l'augmentation de capital envisagée
Prix de souscription : 1,80€ par action, soit une décote de 29,4% par rapport au cours de clôture de l'action le 22 octobre 2025
Parité de souscription : 6 actions no...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
REC
LISTED
EURONEXT
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
News Preview
NEWS RELEASE...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
ACB
LISTED
NASDAQ
Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call
News Preview
NASDAQ | TSX: ACB
EDMONTON, AB, Oct. 22, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
ACB
LISTED
NASDAQ
Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call
News Preview
NASDAQ | TSX: ACB
EDMONTON, AB, Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
ICLR
LISTED
NASDAQ
ICON Reports Third Quarter 2025 Results
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the third quarter ended September 30, 2025.
CEO, Mr. Barry Balfe commented, “ICON’s results in quarter three were reflective of broad market conditions, as we continued to partner with customers to navigate an uncertain environment....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
SN
LISTED
LSE
UFC® and Smith+Nephew announce multi-year extension of partnership
News Preview
Smith+Nephew to continue as UFC’s Preferred Sports Medicine Technology Partner...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
NKTR
LISTED
NASDAQ
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
News Preview
SAN FRANCISCO, Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
SLP
LISTED
NASDAQ
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and managemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
News Preview
CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the o...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
CTXR
LISTED
NASDAQ
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
News Preview
CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered d...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
NUTX
LISTED
NASDAQ
Deadline Soon: Nutex Health Inc. (NUTX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) securities between August 8, 2024 and August 14, 2025, inclusive (the “Cla...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
TEM
LISTED
NASDAQ
Tempus to Report Third Quarter 2025 Financial Results on November 4
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET.
The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Office...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
CTXR
LISTED
NASDAQ
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
News Preview
CRANFORD, N.J., Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreement for th...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
CYRX
LISTED
NASDAQ
Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025
News Preview
NASHVILLE, Tenn., Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2025 on Tues...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
SOBI
LISTED
STO
Change in the Sobi Board of Directors
News Preview
STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned her position effective immediately. She will be nominated for election to the board of another company which is serving the healthc...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
SOBI
LISTED
STO
Change in the Sobi Board of Directors
News Preview
STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned her position effective immediately. She will be nominated for election to the board of another company which is serving the healthc...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
BAVA
LISTED
CPH
Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer to the shareholders of Bavarian Nordic
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
GMAB
LISTED
CPH
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
News Preview
Media ReleaseCOPENHAGEN, Denmark; October 21, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
OGI
LISTED
NASDAQ
Organigram Global Announces Update to CEO Succession Plan
News Preview
Organigram Global Inc. (“Organigram” or the “Company”) announces that Ms. Beena Goldenberg will extend her tenure as Chief Executive Officer until November 30, 2025 to support the completion of the Company’s ongoing CEO search process.
The Board’s search has attracted strong interest and they are pleased with the progress as they focus on identi...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
BAYN
LISTED
XETR
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
News Preview
Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming 17th World Stroke Congress, being held in Barcelona, Spain from October 22 – 24.
Bayer presentations on OCEANIC-STROKE include:
Factor XIa (FXIa)...
Themefolio
Profiler
Peergroup
© Newsfile
21.10.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
News Preview
Dublin, Ireland--(Newsfile Corp. - October 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults an...
Themefolio
Profiler
Peergroup
© EQS Newswire
21.10.2025
SOON
LISTED
SIX
Sonova baut KI-Führungsposition aus und lanciert Innovationen an der
EUHA 2025
News Preview
Sonova Holding AG
/ Schlagwort(e): Produkteinführung
Sonova baut KI-Führungsposition aus und lanciert Innovationen an der
EUHA 2025
21.10.2025 / 07:00 CET/CEST
Group Media & Investor Release
Stäfa (Schweiz), 21. Oktober 2025 – Sonova Holding AG (SWX: SOON) baut ihre Führungsrolle beim Einsatz Künstlicher Intelligen......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.10.2025
SOON
LISTED
SIX
Sonova expands AI leadership with innovations debuting at
EUHA 2025
News Preview
Sonova Holding AG
/ Key word(s): Product Launch
Sonova expands AI leadership with innovations debuting at
EUHA 2025
21.10.2025 / 07:00 CET/CEST
Group Media & Investor Release
Stäfa (Switzerland), October 21, 2025 – Sonova Holding AG (SWX: SOON), takes its AI leadership in hearing care further by introducing Infinio......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.10.2025
FYB
LISTED
XETR
FYB201/Ranivisio® ist das erste Ranibizumab-Biosimilar Europas in einer Fertigspritze
News Preview
Pressemitteilung // 21. Oktober 2025
Formycon setzt neuen Standard: FYB201/Ranivisio® ist das erste Ranibizumab-Biosimilar Europas in einer Fertigspritze
Innovative Fertigspritze (PFS) für intravitreale Injektionen¹ bietet verbessertes Handling sowie hohe Dosiergenauigkeit und Anwenderfreundlichkeit
Teva Pharmaceutical Industries Ltd. übernimm......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.10.2025
FYB
LISTED
XETR
Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
News Preview
Press Release // October 21, 2025
Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Innovative pre-filled syringe (PFS) with high standards for intravitreal injections1 offers improved handling, high dosing accuracy and greater convenience for applicants
Teva Pharmac......
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
GLPG
LISTED
EURONEXT
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
News Preview
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
NUTX
LISTED
NASDAQ
NUTX Deadline: Rosen Law Firm Urges Nutex Health Inc. (NASDAQ: NUTX) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025. Nutex describes itself as a “physician-led, healthcare services and operations company.”
For more information, submit a...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
News Preview
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
TEM
LISTED
NASDAQ
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
News Preview
Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
CTXR
LISTED
NASDAQ
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
News Preview
McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR
CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
News Preview
The first patient has been dosed in the Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis....
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
GMAB
LISTED
CPH
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
News Preview
Media Release COPENHAGEN, Denmark; October 18, 2025...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
